Koyun Derya, Seval Güldane Cengiz, Kırcalı Ekin, Bozdağ Sinem Civriz, Toprak Selami Koçak, Topçuoğlu Pervin, Özcan Muhit, Arslan Önder, Demirer Taner, İlhan Osman, Beksaç Meral, Gürman Günhan, Yüksel Meltem Kurt
Ankara University School of Medicine, Hematology Department, Ankara, Turkey.
Indian J Hematol Blood Transfus. 2022 Jul;38(3):601-605. doi: 10.1007/s12288-022-01524-2. Epub 2022 Feb 7.
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) treatment has a low response rate and a high risk of infection in allogeneic hematopoietic stem cell transplantation. The standard approach to be applied in this situation is uncertain. This study aims to evaluate the effectiveness and safety of alpha-1-antitrypsin (AAT). In the study, the results of five SR-aGVHD patients received AAT evaluated. Complete response was seen 2 of four patients with gastrointestinal (GI) aGVHD, partial response in one GI and one liver aGVHD. The overall response rate was 80%. AAT is an effective and safe treatment option in SR-aGVHD.
在异基因造血干细胞移植中,类固醇难治性急性移植物抗宿主病(SR-aGVHD)的治疗缓解率低且感染风险高。在这种情况下应用的标准方法尚不确定。本研究旨在评估α-1抗胰蛋白酶(AAT)的有效性和安全性。在该研究中,对5例接受AAT治疗的SR-aGVHD患者的结果进行了评估。4例胃肠道(GI)aGVHD患者中有2例出现完全缓解,1例GI aGVHD和1例肝脏aGVHD患者出现部分缓解。总缓解率为80%。AAT是SR-aGVHD一种有效且安全的治疗选择。